• Mixed hyperlipidemia when statin is contraindicated or not tolerated.
Dosage & Administration:
Patients with renal insufficiency: In moderate renal impairment (creatinine clearance 30-80 ml/min/1.73m2) it is recommended that dosage be reduced to one tablet every other day. Patients should be carefully monitored. Ciprofibrate should not be used in severe renal impairment (creatinine clearance <30 ml/min/1.73m2).
Patients with hepatic insufficiency: Use with caution in patients with impaired hepatic function. Ciprofibrate treatment should be discontinued in case of increased AST and ALT levels to more than 3 times the upper limit of normal or if cholestatic liver injury is evidenced.
Elderly: As for adults but precautions should be taken for Age more than 70 years.
Paediatric population: Not recommended since safety and efficacy in children has not been established.